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Background. CD4+ T cell help is critical in maintaining antiviral immune responses and such help has been shown to be
sustained in acute resolving hepatitis C. In contrast, in evolving chronic hepatitis C CD4+ T cell helper responses appear to be
absent or short-lived, using functional assays. Methodology/Principal Findings. Here we used a novel HLA-DR1 tetramer
containing a highly targeted CD4+ T cell epitope from the hepatitis C virus non-structural protein 4 to track number and
phenotype of hepatitis C virus specific CD4+ T cells in a cohort of seven HLA-DR1 positive patients with acute hepatitis C in
comparison to patients with chronic or resolved hepatitis C. We observed peptide-specific T cells in all seven patients with
acute hepatitis C regardless of outcome at frequencies up to 0.65% of CD4+ T cells. Among patients who transiently controlled
virus replication we observed loss of function, and/or physical deletion of tetramer+ CD4+ T cells before viral recrudescence. In
some patients with chronic hepatitis C very low numbers of tetramer+ cells were detectable in peripheral blood, compared to
robust responses detected in spontaneous resolvers. Importantly we did not observe escape mutations in this key CD4+ T cell
epitope in patients with evolving chronic hepatitis C. Conclusions/Significance. During acute hepatitis C a CD4+ T cell
response against this epitope is readily induced in most, if not all, HLA-DR1+ patients. This antiviral T cell population becomes
functionally impaired or is deleted early in the course of disease in those where viremia persists.
Citation: Lucas M, Ulsenheimer A, Pfafferot K, Heeg MHJ, Gaudieri S, et al (2007) Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis
C Virus Infection. PLoS ONE 2(7): e649. doi:10.1371/journal.pone.0000649
INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of chronic liver
disease worldwide and is thought to affect over 170 million people
[1]. The virus readily sets up persistent infection in the majority of
those who acquire it, evading host innate and adaptive immunity.
A smaller proportion of those infected, however, do spontaneously
control virus infection–in these, cellular immune responses are
thought to play an important role [2,3]. Functional assays and
genetic studies point to a prominent role of HCV-specific CD4+
and CD8+ T cells in this initial control, as well as innate responses
driven by NK cells and neutralising antibodies [4–6]. Animal
models of HCV demonstrate a key role for CD4+ T cells,
especially upon rechallenge [7]. Until recently, direct evaluation of
virus-specific CD4+ T cells has not been possible, except in
transgenic systems. However, recent advances in HLA class II
tetramer technology and improvements in staining techniques
have allowed CD4+ T cell populations to be observed ex vivo in
a variety of settings, including HCV, influenza and HIV [8–11].
These tools are based on the refolding of soluble, biotinylated
HLA class II molecules with specific viral peptides in vitro, and
tetramerisation around fluorescently labelled streptavidin mole-
cules to allow strong binding of the complex with the T cell
receptor of the specific cells present within a population. Typically
these cells occur at low frequencies, 1-2 logs lower than those
detected with class I-peptide tetramers, which bind CD8+ T cells.
Using magnetic bead enrichment techniques, however, the HLA
class II tetramer staining can reliably detect populations of specific
CD4+ T cell as small as 0.001% of total CD4+ T cells
(corresponding to 10/10
6) [9,12–14].
Here we present the first longitudinal study with HLA class II
tetramers in patients with different outcomes of acute hepatitis C.
We took advantage of an unusually immunodominant, HLA-DR1
restricted CD4+ T cell epitope which we had characterized in
detail by specific CD4+ T cell clones from three different patients
and which was complexed into an HLA-DR1 tetramer. This novel
tetramer was used to explore the frequency, phenotype and
function of hepatitis C virus (HCV)-specific CD4+ T cells in seven
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viral elimination or persistence. We identified a novel pattern of
dynamics of helper cell populations associated with viral
persistence, which is likely to be critical in the evolution of HCV
towards persistent infection.
MATERIALS AND METHODS
Patients
Seven HLA-DR1 positive patients with acute hepatitis C were
included in this study. All patients were available for study within
the first 3 months after onset of symptoms. Acute hepatitis C was
diagnosed by documented seroconversion to anti-HCV anti-
bodies or all of the following: acute onset of hepatitis in previously
healthy individual, aminotransferases at least 106the upper limit
of normal, exclusion of other infectious, metabolic, or toxic
causes of hepatitis, recent exposure or source of infection
identified. The clinical characteristics of the patients are
summarized in Table 1.
Five HLA-DR1 positive patients with established chronic
hepatitis C (HCV-RNA positive, anti-HCV positive) and two
long-term recovered patients (anti-HCV positive, HCV-RNA
negative) were studied for CD4+ T cell responses in peripheral
blood (Table 1). In six other HLA-DR1 positive patients with
chronic hepatitis C liver derived T cell lines were analysed; the
clinical details of these have been reported previously [15].
Four healthy and four HIV-infected HLA-DR1-positive
individuals, as well as two healthy and five acutely HCV-infected
HLA-DR1-negative individuals (n=15) served as controls.
All patients gave informed consent to participate in the study
and the protocol and the procedures of the study were conducted
in conformity with the ethical guidelines of the Declaration of
Helsinki. The patients with acute and chronic hepatitis C were
recruited at the University Hospital Munich or at the University
of Freiburg (for intrahepatic T cell lines [15]) according to study
protocols approved by the local ethical committee. The sequence
data are derived from the Genetic Cohort of the Swiss HIV
Cohort study (www.shcs.ch) that have all given informed consent
for use of clinical data, viral sequencing and genetic analyses.
The HIV positive controls were recruited from an ethically
approved study of St Mary’s Hospital, London, UK (protocol
99/IA/161E).
HCV proteins and peptides
Recombinant HCV proteins were kindly provided by M.
Houghton (Chiron, Emeryville, CA) comprising the non-structural
protein 4 (NS4) or/and the non-structural protein 3 (NS3) region
of the HCV polyprotein (c100, c200). Proteins were expressed as
COOH-terminal fusion proteins with human superoxide dismu-
tase in yeast (Saccharomyces cerevisiae). Protein was .90% pure.
Eighty-three overlapping peptides (20mers) covering the region
amino acid (aa) 1207–2014 were synthesized by Chiron Mimo-
topes (Clayton, Australia) and 301 overlapping peptides (15mers)
covering the entire HCV polyprotein were synthesized by EMC
(Microcollections, Tu ¨bingen, Germany).
Proliferation assay
Peripheral blood mononuclear cells (PBMC) were isolated on
Ficoll-Hypaque gradients (Biochrom, Berlin, Germany) and
washed four times in phosphate buffered saline (PBS). PBMCs
(5610
4 cells/well) were incubated in 96-well U-bottom plates
(TPP, Trasadingen, Switzerland) for 5 days in the presence of
HCV proteins (2 mg/ml; c100) in 150 ml of tissue culture
medium (RPMI 1640 medium; Biochrom, Berlin, Germany)
containing 2 mM L-glutamine, 1 mM sodium pyruvate (Serva,
Heidelberg, Germany), 100 U of penicillin (Biochrom, Berlin,
Germany) per ml, 100 mg of streptomycin (Biochrom, Berlin,
Germany) per ml and 5% human AB serum (Pan, Aidenbach,
Germany). Cultures were labelled by incubation for 16 h with
2 mCi of 3H-thymidine (specific activity, 80 mCi/mmol; Amer-
sham, Little Chalfont, United Kingdom). Triplicate cultures
were assayed routinely, and the results expressed as mean counts
per minute. The stimulation index (SI) was calculated as the
ratio of counts per minute obtained in the presence of antigen to
that obtained without antigen. A SI of .3w a sc o n s i d e r e d
significant.
Elispot assay
Nitrocellulose-bottom 96-well millititer HA plates (Millipore,
Bedford, MA) were coated with 100 ml of IFN-gamma monoclonal
antibody (Mabtech, Stockholm, Sweden), at a concentration of
15 mg/ml in PBS. Plates were incubated at 4uC overnight; before
use unbound antibody was removed by excessive washing with
PBS. The coated wells were filled with 100 ml tissue culture
medium containing 2610
5 freshly isolated PBMC and NS4
protein (c100, 2 mg/ml). After 48 h incubation, cells were washed
off and the biotin-conjugated anti-IFN gamma antibody (Mab-
tech, Stockholm, Sweden, 1 mg/mL) was added. After an
incubation period (4 h, room temperature) unbound antibody
was washed off and 100 ml of the streptavidin-alkaline phosphatase
(Mabtech, Stockholm, Sweden) was added for 1 h. Unbound
conjugate was washed off and, finally, 100ml of 5-bromo-4-chloro-
indolylphosphate/nitroblue tetrazolium substrate solution (Bio-
Rad Lab., Richmond, CA) was added for 2 h. The colour reaction
was stopped by extensive washing. After drying the number of
spots was scored by use of a dissection microscope.
Table 1. Clinical data of patients with acute hepatitis C
......................................................................
Patient Sex Route of infection Therapy Outcome Genotype
Acute-Resolver (mean age 44.5 years)
AR1 F hospital None Resolved nd
AR2 F unknown IFN+RBV SR 1a
Acute-Chronic (mean age 26.8 years)
AC1 F i.v. drugs None Chronic 1b
AC2 M hospital None Chronic 1b
AC3 M i.v. drugs IFN+RBV SR 1b
AC4 F unknown IFN+RBV SR nd
Acute–lost to follow-up
AX F i.v. drugs None unknown nd
Long-term Resolver (mean age 32 years)
R1 F sexual None Resolved 1a
R2 F blood product None Resolved 1
Chronic hepatitis C (mean age 42 years)
C1 M unknown None 1
C2 M unknown None 1b
C3 M unknown None 2
C4 F i.v drugs IFN+RBV NR 3a
C5 F unknown None 1b
IFN=interferon-alpha; RBV=ribavirin; NR=non-responder to antiviral therapy;
SR=sustained responder to antiviral therapy.
doi:10.1371/journal.pone.0000649.t001
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The DRB1*0101 tetramer complexed with HCV 1806-1818
(TLLFNILGGWVAA) was custom synthesized by Beckman
Coulter Immunomics (France, Marseille). PBMC were stained in
100 ml medium (RPMI, 10% fetal calf serum, 2 mM glutamine,
50 U/ml Penicillin-Streptomycin) with 3 ml of Phycoerythrin (PE)-
conjugated MHC class II tetramer for 2 hours at room
temperature. Allophycocyanin-conjugated anti-CD4, Peridinin
Chlorophyll-a Protein-conjugated anti-CD14, Peridinin Chloro-
phyll-a Protein-conjugated anti-CD19, Viaprobe (Becton Dick-
inson), and FITC-conjugated anti-CD38 monoclonal antibody
(Becton Dickinson) were added after at least 20 minutes of
incubation. Cells were washed twice and then incubated with anti-
PE microbeads for 20 minutes at 4uC. Cells were then washed
once and 90% of cells were applied to MS columns (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufac-
turer `s instructions. The other 10% were reserved for FACS
analysis. The PE positive cells were eluted from the column (post-
enrichment sample) and analyzed by FACS. Cells were gated on
the CD4+, CD14-, CD19- and Viaprobe-population.
Calculation of tetramer-positive T cell frequencies
and validation of the method
Frequencies of tetramer-positive CD4+ T cells were determined as
described previously [9,12–14]. Briefly, the input number of
CD4+ T cells in the enriched sample (90% of total) was calculated
by multiplying the number of CD4+ cells in the pre-enrichment
sample (10% of total) by a factor of 9. The frequency of tetramer-
positive cells was thus calculated by dividing the post-enrichment
output number of tetramer-positive cells by the calculated input
number of CD4+ cells.
Expansion of liver infiltrating lymphocytes
Biopsies were obtained in patients with chronic hepatitis as
clinically indicated. From material not needed for histological
analysis, lymphocytes were isolated and expanded as explained
previously [15]. In brief, homogenized cell suspensions were
incubated with magnetic beads coupled to anti- CD4 antibodies,
and bound cells were isolated using a particle magnetic
concentrator. The purity of the T-cell subset, which was confirmed
by fluorescence-activated cell sorting (FACS) analysis, was always
greater than 90%. The isolated intrahepatic T cells were then
plated into separate wells in 24-well plates (Greiner, Essen,
Germany) in 1 mL 10% human AB serum, 100 U/mL IL-2
(Hoffmann–La Roche, Basel, Switzerland), 0.04 mg/mL anti-
human CD3 monoclonal antibody (Immunotech, Marseilles,
France), and 2610
6 irradiated autologous PBMCs as feeder cells.
Sequencing
Viral RNA was extracted from plasma samples using either the
QIAamp Viral RNA Mini Kit (QIAGEN) or the COBAS
AMPLICOR HCV Specimen Preparation Kit v2.0 (Roche)
according to manufacturer’s instructions. An initial RT-PCR
using the primers 2412F2 (CACCTCCACCARAACATYGT)
and 9192R (GGAGTGAGTTTGAGCTTGGT) in combination
with the SuperScript III One-Step RT-PCR System with Platinum
Taq DNA polymerase PCR Kit (Invitrogen) was performed. The
first-round product was then used in nested 2nd round PCRs to
amplify the relevant NS4 region with the following primer pairs,
HCV-5040F/HCV-HCV-6121R (CACATAGATGCCCACTTCCT/
GCCCCGGGAGGCRAASGC) and HCV-6076F/HCV-7636R
(CTGTGCARTGGATGAACMG/TGATGAGGGCSCCKGTCCA)
or alternatively the genotype 1-specific primers 5517M13F/6531M13R
(GAGCARTTCAAGCAGAAGGCSCTC/AGGGGCCCGTGGTG-
TABGCGTT) together with the Platinum Taq DNA Polymerase High
Fidelity Kit (Invitrogen). PCR products were purified using the Exosap
method (Amersham) and BigDyeTerminator (v3.1) sequencing reactions
were set up with PCR or M13 primers. The samples were run on an ABI
3730 Genetic Analyser and electropherograms analysed using Seqscape
v2.0 (ABI).
HLA Typing
DNA was obtained from whole blood using the QIAamp DNA
Blood Mini Kit following the manufacturer’s guidelines. HLA
Class II typing was performed by PCR and/or direct DNA
sequencing using previously described methods [16].
RESULTS
Validation of the HLA-DR1-HCV-1806-1818 tetramer
and staining of specific CD4+ T cell clones
For tetramer synthesis we selected the epitope HCV-1806-1818
which has previously been shown to be a highly targeted epitope in
HLA-DR1 positive patients with acute or resolved hepatitis C
[17,18]. This HLA-DR1 tetramer strongly and specifically stained
epitope specific CD4+ T cell clones from both HLA-DRB1*0101
and *0102 positive individuals (Figure 1A+B). Since the expected
frequency of virus specific CD4+ T cells in PBMC was below 0.1%
of CD4+ T cells we employed an enrichment technique using
antibodies to PE coupled to magnetic beads that allows accurate
quantification of rare populations of antigen-specific cells above
0.001% of input CD4+ T cells, corresponding to 10/10
6 CD4+ T
cells [9,12–14]. To test the accuracy of the assay, we titrated
specific clone cells into autologous PBMC which had been
depleted of specific CD4+ T cells. Over a range of 0.01 to 5%
epitope specific CD4+ T cells could reliably be enumerated
(Figure 1C). The enrichment technique was validated in PBMC
samples with a frequency of tetramer positive cells .0.03% (n=12
time points), because in those samples a valid frequency
determination could be performed both before and after
enrichment. A high agreement was found with a R2 of 0.99
(p,0.001, Figure 1D).
In the controls a mean of 0.7360.75 tetramer+ CD4+ T cells
(range 0–2) were found among a mean of 0.5610
6 CD4+ T cells
that were analysed, corresponding to a mean frequency of
0.0001660.00017% of CD4+ T cells (Figure 1E).
Representative dotblots of the HLA class II tetramer staining in
patients AR1 and AC1 before and after enrichment are shown in
Figure 2 and an example of the frequency calculation is given in
the figure insert.
Acute study population and clinical course
A cohort of seven HLA-DR1 positive persons with acute hepatitis
C was available for study (Table 1). Five of those were sampled
longitudinally from the first weeks of acute disease (median
4 weeks after onset of symptoms, range 1–90 days) for a mean
follow-up of 21 months (range 6 to 42 months). One individual
cleared spontaneously (AR1); another one had cleared spontane-
ously but received interferon-alpha treatment after three months
despite negative HCV-RNA in the serum because of continuously
elevated ALT levels and fear of relapse (AR2). Three of the cohort
achieved transient viral control for 20, 21, and 6 weeks,
respectively, before recrudescence of HCV-RNA in the serum
(AC1-3). Of these, one patient (AC3) was treated successfully with
interferon-alpha and ribavirin, one patient refused treatment
HCV Specific CD4+ T Cells
PLoS ONE | www.plosone.org 3 July 2007 | Issue 7 | e649Figure 1. Validation of HLA-DR1-HCV-1806-1818 tetramer staining and enrichment technology. A CD4+ T cell clone specific for HCV 1808-1817
was stained with the HLA-DR1-HCV-1806-1818 tetramer and a control HLA-DR1 tetramer specific for the influenza epitope 307-319 and analysed by
flow cytometry as described in the methods (A+B). The HCV clone was derived from patient AR1. Panel C shows staining of the clone diluted serially
into PBMC negative for the tetramer at the concentrations shown. Panel D shows a strong correlation between observed pre-enrichment frequency
and calculated post-enrichment frequency of HLA-DR1-HCV-tetramer positive CD4+ T cells in all PBMC samples with a frequency of HLA-DR1-HCV-
tetramer positive CD4+ T cells of .0.03% (R
2=0.99, p,0.001). The dotted line is the bisecting line, the solid line represents the trend line of the
measured frequencies. Panel E shows the staining of control groups; four healthy and four HIV-infected HLA-DR1 positive individuals, and two
healthy individuals and five acute hepatitis C patients without HLA-DR1.
doi:10.1371/journal.pone.0000649.g001
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PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e649(AC1) and patient AC2 had medical contraindications to antiviral
treatment. The clinical course (ALT and viral load over time) of
individuals AR1 and 2 and AC1-3 is shown for each person in
Figure 3 (upper panel in each case).
The two other HLA-DR1 positive individuals with acute
hepatitis C were available for study at a single time point one
and four weeks after onset of disease, respectively. One was still
viremic after 4 months and was treated successfully with
Figure 2. Examples of ex vivo HLA-DR1-HCV-1806-1818 tetramer staining from the acute hepatitis C cohort. PBMC from one acute resolving
patient (AR1) and one patient with acute hepatitis C and chronic evolution (AC1) were stained with the HLA-DR1-HCV-1806-1818 tetramer as
described in the methods. For each patient the upper panels represent pre-enrichment stainings and the lower-panels the post-enrichment stainings.
The numbers in the upper right corner of the post-enrichment panels are calculated according to the input CD4+ T cell number. The insert on top of
the figure shows in detail the calculation method. These figures are plotted over time in both cases in Figure 2 (lower panels).
doi:10.1371/journal.pone.0000649.g002
HCV Specific CD4+ T Cells
PLoS ONE | www.plosone.org 5 July 2007 | Issue 7 | e649HCV Specific CD4+ T Cells
PLoS ONE | www.plosone.org 6 July 2007 | Issue 7 | e649antiviral therapy (AC4), and the other was lost to follow-up
(AX).
Epitope HCV-1808-1817 is highly targeted in our
study cohort
In four of the five longitudinally studied patients (AR1, AC1-3)
proliferation assays with overlapping peptide libraries were
performed to define the hierarchy of immunodominant epitopes
(Figure 4). One peptide library was composed of 301 over-
lapping 15-mer peptides covering the entire HCV polyprotein,
the other peptide library contained 83 overlapping 20-mer
peptides covering NS3-helicase-NS4 (aa 1207–2014). The first
library was used at eight time points (patients AR1, AC2, and
AC3), the second library was used at three time points (patients
AR1 and AC1). Importantly, in all patients the response to
peptides containing the epitope present in the HLA-DR1-HCV-
1806-1818 tetramer was strongest, indicating that the CD4+ T
cell response against this epitope represents a major part of the
overall HCV-specific T helper response in HLA-DR1 positive
patients.
HLA-DR1-HCV-1806-1818 tetramer staining
Tetramer+ CD4+ T cells were detected in all seven patients with
acute hepatitis C, irrespective of clinical outcome, with frequencies
ranging from 0.007% to 0.65% (mean 0.16%+/20.2). Represen-
tative stainings from patients AR1 and AC1 showing both pre-
enrichment and post-enrichment samples are displayed in Figure 2;
the detailed correlation with ALT, viral load, HCV specific
proliferation, and IFN-c secretion of all five patients is shown in
Figure 3. In the two patients with acute hepatitis C who were
Figure 4. Relative immunodominance of epitope HCV 1805-24 in the acute HCV cohort. Ex vivo proliferation assays were performed on PBMC
taken from the persons indicated over time. The responses to peptides including the sequence 1807-18 are marked with a dark bar. The ten peptides
inducing the strongest proliferative response are shown in descending order with regard to the strength of the response. Asterisks indicate time
points when the NS3-helicase/NS4 peptide library (covering aa 1207–2014) was used; all other assays were performed with a peptide library covering
the entire HCV genome. A SI.3.0 was considered significant.
doi:10.1371/journal.pone.0000649.g004
r
Figure 3. Clinical course of acute hepatitis C cohort in correlation to HCV specific CD4+ T cell response. The clinical course of each individual is
shown in the upper panel in each case. Note the time scale (days) is different in each case. The upper panel shows the ALT (IU/L; open boxes; left
hand y axis) and the serum HCV RNA level (closed triangles; right hand y axis). For AR1, AR2 and AC3, at some time points only qualitative assays for
HCV-RNA were available which have been marked with a +. Interferon alpha therapy is marked with a bar. In patients AC1 and AC2 time points where
the sequence of epitope 1806-1818 was determined are indicated by arrows. The middle panel in each case corresponds to functional CD4+ T cell
assays: proliferation in response to NS3/4-antigen (open boxes) and peptide-1806-1818 (open triangles) is shown as stimulation index (SI) on the left
hand y axis and HCV-antigen induced interferon-gamma secretion as determined by Elispot (solid diamonds) is shown as spot forming units (SFU) on
the right y-axis. The lower panel of each case shows the frequency of HLA-DR1-HCV-1806-1818 tetramer positive CD4+ T cells (grey circles). The cut-
off for detection was 0.001%. The upper limit of normal for ALT is indicated in panel AR2 as dotted line.
doi:10.1371/journal.pone.0000649.g003
HCV Specific CD4+ T Cells
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tetramer+ CD4+ T cell were 0.05% and 0.007%, respectively.
In patient AR1, the highest frequency of tetramer+ CD4+ T
cells (0.65% of peripheral CD4+ T cells) was measured at the
earliest time point which was 2 weeks after spontaneous clearance
of HCV-RNA from the serum. Tetramer+ CD4+ T cells
subsequently declined to a level of about 0.1% and remained
stable for more than 3.5 years of follow-up. Very strong peptide
specific T cell proliferation and NS4-specific IFN-gamma
secretion were present during the first 6 months after disease
onset, and -despite some fluctuations-robust responses were
maintained during long-term follow-up.
In patient AR2, relatively high levels of tetramer+ CD4+ T cells
(0.12%) and significant T cell proliferation were present during the
phase of viral clearance. At week 12 the frequency of tetramer+
CD4+ T cells declined by one log and proliferation was lost.
Despite the continuing absence of HCV-RNA from the serum at
that time, the constantly elevated ALT levels suggested a high risk
of viral relapse and interferon-alpha treatment was initiated. The
frequency of tetramer+ CD4+ T cells recovered to the initial levels
and finally remained around 0.05% during the follow-up after
antiviral therapy. T cell proliferation was detected only in-
termittently during and after interferon-alpha treatment.
All three patients with chronic evolution went through a phase
of undetectable serum HCV-RNA in the first six months of
disease. In all three, tetramer+ CD4+ T cells and significant
antigen-specific proliferation were present during viral clearance
and the first phase of viral control; antigen-specific proliferation,
however, was completely lost in all three patients when viral
relapse occurred. In patients AC2 and AC3 simultaneous IFN-c
Elispot assays revealed that IFN-c secretion was absent even
earlier. In patient AC3 this occurred three weeks before the loss of
proliferation; in patient AC2 IFN-c secretion could never be
detected. Importantly, in AC2 and AC3 the loss of function
occurred while the frequency of circulating tetramer+ CD4+ T
cells was relatively stable at levels between 0.04% and 0.14%.
While in patient AC2 the frequency of tetramer+ CD4+ T cells
subsequently declined and eventually specific cells disappeared,
successful interferon therapy in AC3 was associated with stable
levels of tetramer+ CD4+ T cells although only a modest recovery
of function was measurable. A different pattern was seen in patient
AC1: here, the tetramer+ CD4+ T cells had already disappeared
from the peripheral blood before viral recrudescence and only very
low frequencies (0.003%) could be detected, intermittently, during
the subsequent months. Importantly, in no case was the loss of
HCV-specific CD4+ T cell function accompanied by a relevant
decrease of recall antigen (tetanus toxoid) or mitogen (PHA)
responses.
Expression of the activation marker CD38 on
tetramer+ CD4+ T cells
Longitudinal phenotyping for CD38 was routinely performed with
all tetramer stainings; in the first samples that could be studied,
between 5.8 and 32% of tetramer positive cells expressed CD38.
In contrast, at all time points beyond 6 months, CD38 expression
was negative in both recovered and chronically infected patients.
Representative experiments are shown in Figure 5. In patient AR1
only 5.6% of tetramer+ CD4+ T cells were CD38 positive on day
22 which was 2 weeks after viral elimination, and well after the
ALT peak. In all subsequent assays, CD38 was absent on
tetramer+ CD4+ T cells. In contrast, in patient AC3 CD38
expression actually increased again to 19% when HCV-RNA re-
appeared in the serum. The highest levels of CD38 expression on
tetramer+ CD4+ T cells, 28% and 32%, respectively, were
measured in patient AC1 just before tetramer+ CD4+ T cells were
lost. Overall, we did not see very high levels of CD38 expression in
this cohort, compared to studies using class I tetramers [4,19].
HLA-DR1-HCV-1806-1818 tetramer staining in
patients with chronic hepatitis C and long-term
resolvers
In HLA-DR1 positive patients with chronic hepatitis C a mean of
0.0032%+/2 0.0025 of CD4+ T cells stained tetramer+ (n=6;
range ,0.001% to 0.0063%), which is more than 1.5 logs below
the mean frequency of tetramer+ CD4+ T cells in patients in the
early phase of acute hepatitis C, although still in some cases
higher than the control stainings (DR1+HCV- and DR1-HCV+)
which were all ,0.001% (mean 0.00017%; Figure 6). In contrast,
three patients with a history of spontaneous HCV clearance,
including patient AR1 three years after viral clearance, main-
tained mean levels of tetramer+ CD4+ T cells of 0.064%+/2
0.03 (range 0.038% to 0.1%) for up to 20 years after acute
hepatitis C.
One possible explanation for the results seen would be that
virus-specific CD4+ T cells are compartmentalised entirely in the
liver, once persistent infection is established. We therefore studied
CD4+ T cells from six liver biopsies taken from chronically
infected HLA DR1+ patients in parallel with peripheral blood
samples. In no case was a detectable tetramer+ population seen
(data not shown) whereas in parallel, using similar antigen-
independent stimulation techniques, in the same cohort of patients
substantial class I tetramer+ CD8+ T cell populations were
visualised [15]. It is, however, conceivable that HCV-specific
CD4+ T cells–in contrast to CD8+ T cells–are lost in vitro during
the expansion step and further studies with an optimised protocol
for direct ex-vivo HLA class II tetramer staining of liver infiltrating
lymphocytes will need to be performed to resolve this issue.
Analysis of immune selection within the HLA DR1
immunodominant epitope
Another explanation for the clear loss of tetramer+ populations,
and loss of responsiveness associated with chronic infection would
potentially be immune escape within the target epitope. To
address this question, we sequenced early and late viral samples
from patients AC1 and AC2. In patient AC3 no HCV sequence
could be obtained probably due to the low viral load before
antiviral therapy was initiated. In both early and late samples the
sequence within epitope 1805-1824 corresponded to the prototype
sequence (Table 2). To further expand this data we added
a population-based approach, as has been used in the evaluation of
CD8+ T cell responses to HCV restricted by HLA-B8 [20] and
B27 [21]. We analyzed the sequences in 8 HLA DR1+ individuals
with stable chronic infection, from cohorts in Munich, Australia
and Switzerland and compared this to sequences of 80 HLA DR1-
controls. The data are displayed in Table 3, which reveals a very
limited degree of diversity in this epitope, and a mutation seen in
only 1 out of 8 of the DR1+ patients, a frequency which does not
differ from that in the HLA DR1- control group (10 of 80,
p=n.s.). Given the strong conservation of this peptide sequence, it
seems unlikely that immune escape through mutation is a major
contributor to the decline in T cell responses observed, unless it is
only transient and followed by reversion. Interestingly, while this
epitope is highly conserved within genotype 1 sequences, there is
less sequence conservation if compared to other genotypes (http://
www.bioafrica.net/GDElinux/GDEmicrobial.html).
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In this study we used a novel MHC Class II peptide tetramer for
the detection of HCV-specific CD4+ T cells in HLA DR1+
patients with different stages and courses of HCV infection. This is
the first HCV specific HLA class II tetramer to be tested and
validated using epitope specific CD4+ T cell clones and we could
demonstrate that this tetramer possesses similar sensitivity and
specificity to HIV or influenza specific HLA class II tetramers
characterized in a similar manner [8–11]. In addition, we took
advantage of the fact that the HCV peptide used for the tetramer
synthesis was highly targeted in our HLA-DR1+ study cohort.
This limits the concern inevitably associated with the use of MHC-
peptide tetramers in that they only detect responses against a single
epitope with a single HLA restriction.
The major novel aspect of this study was the analysis of
tetramer+ populations at early time-points after HCV infection,
and most importantly, longitudinal analysis of the fate of these
Figure 5. CD38 expression of HLA-DR1-HCV-1806-1818-tetramer positive CD4+ T cells. Longitudinal phenotypic analysis of the DR1 tetramer
positive cells was performed for the activation marker CD38. The dot plots shown are gated on the DR1 tetramer positive cell population.
Representative examples of the staining for AR1, AC1, and AC3 at early and late time points are shown and the percentage of CD38 positive cells is
given for each plot. The inserted histograms show CD38 staining on all CD4+ T cells pre-enrichment and have been used to set the quadrants for the
DR1 tetramer staining.
doi:10.1371/journal.pone.0000649.g005
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outcome of acute hepatitis C. The data clearly show that
regardless of the long term clinical outcome, CD4+ T cells specific
for this immunodominant epitope are present in all patients with
acute disease. Interestingly, the frequency of tetramer+ popula-
tions in our cohort with acute hepatitis C was among the highest
ever reported with HLA class II tetramers in viral infection studied
ex vivo [9,10,12]. This may in part be due to the immunodomi-
nance of the epitope for HLA-DR1+ patients but it nonetheless
demonstrates that, firstly, comparatively large numbers of HCV
specific CD4+ T cells are induced during the early phase of HCV
infection, and, secondly, the frequency of HCV specific CD4+ T
cells is at least one log below the frequency of HCV specific CD8+
T cell populations.
The subsequent decline of tetramer+ CD4+ T cells mirrors the
kinetics of HCV specific CD8+ T cells in acute hepatitis C that
have been studied with HLA class I tetramers [19]. Importantly,
whereas after spontaneous or treatment induced viral clearance
tetramer+ CD4+ T cells levelled off at frequencies between 0.01%
and 0.1%, the frequency further declined to very low (,0.01%) or
undetectable levels in patients who developed chronic infection.
This finding is consistent with a previous study employing an HCV
specific HLA-DR4 tetramer that found a significant tetramer+
CD4+ T cell population in long-term recovered patients but not in
patients with chronic hepatitis C [8]. Similarly, with the HLA-
DR1 tetramer we found maintained levels of tetramer+ CD4+ T
cells in three spontaneously recovered patients, one of whom had
cleared HCV more than 20 years before, but only low frequencies
in patients with chronic hepatitis.
Possibly the most informative facet of acute hepatitis C is the
phase of transient viral control and subsequent viral recrudescence
in the majority of patients who eventually develop chronic
hepatitis C. It has previously been described that viral relapse is
associated with a loss of T cell proliferative responses to HCV
antigens [22,23]. In addition, a recent case report using an HLA-
DR4 tetramer showed that loss of proliferative capacity can occur
without changes in the frequency of specific CD4+ T cells,
indicating functional impairment rather than physical deletion
[13]. In the current study, all three chronically evolving individuals
went through a phase of transient viral control. In two of them
tetramer+ CD4+ T cells remained detectable at comparable levels
to the early phase indicating a loss of function whereas in the third
patient tetramer+ CD4+ T cells became undetectable before viral
recrudescence. Interestingly, these kinetics are in strong contrast to
what has been observed in patients with acute HIV infection+/2
short course antiretroviral therapy using HLA class II tetramers
[10,11]. Treatment-induced loss of HIV-RNA was associated with
a decline in HIV specific tetramer+ CD4+ T cells, whereas
recrudescence of HIV-RNA after treatment cessation induced
a sharp increase in tetramer+ CD4+ T cells. Untreated patients
also had responses which were sustained throughout the acute
phase of infection. Long-term viremia may eventually be
associated with a decline in tetramer+ cells; this, however, seems
to be much slower than the decline in HCV-specific CD4+ T cells
that we observed in patients with evolving chronic hepatitis C [11].
These data suggest that continued antigen re-encounter alone is
insufficient to explain the loss of HCV specific CD4+ T cells
during acute hepatitis C. Addressing compartmentalization of
HCV specific CD4+ T cells to the liver is very difficult due to the
lack of availability of liver biopsies from patients with acute
Figure 6. Ex vivo HLA-DR1-HCV-1806-1818 tetramer staining in stable
resolved and chronic HCV infection. Tetramer staining was performed
in five HLA-DR1-positive patients with chronic hepatitis C in comparison
to three HLA-DR1-positive resolved patients. In all PBMC from control
groups (five individuals with acute HCV who did not possess HLA-DR1,
and four healthy and four HIV1+ individuals with HLA-DR1, respective-
ly), tetramer staining was ,0.001%. In all patients and healthy controls,
proliferation assays following stimulation with recombinant NS4-
antigen were performed. The SI for healthy controls was 1.260.48
(mean6SD, range 0.71 to 1.66), for chronic hepatitis C patients 1.760.9
(range 0.76 to 3.7), and for recovered patients 22.1622.1 (range 1.74 to
52.9).
doi:10.1371/journal.pone.0000649.g006
Table 2. Sequence evolution of epitope 1806-1818 in acute
hepatitis C.
......................................................................
Pt. Time point Sequence aa 1806-1818
AC1
day 7 TLLFNILGGWVAA
day 37 -------------
day 347 -------------
AC2
day 101 TLLFNILGGWVAA
day 548 -------------
doi:10.1371/journal.pone.0000649.t002
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Table 3. Sequence of epitope 1806-1818 in chronic hepatitis C
in relation to the presence of the HLA-DR1 allele.
......................................................................
HLA-DR1 positive(n=8) HLA-DR1 negative (n=80)
sequence frequency sequence frequency
TLLFNILGGWVAA 7/8 TLLFNILGGWVAA 70/80
---L--------- 1/8 ---L--------- 2/80
----------M-- 1/80
-----V------- 1/80
---------Z--- 1/80
-Z----------- 1/80
------F------ 1/80
---C------L-- 1/80
----------L-- 1/80
-------X----- 1/80
The consensus sequence for the epitope aa 1806-1818 as used in the tetramer
and functional assays is shown in full, and identity at a residue indicated by
a dash. Z and X represent ambiguous residues within the bulk sequence.
Any mutation in epitope associated with DR1, p=NS
doi:10.1371/journal.pone.0000649.t003
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HLA-DR1 positive patients with chronic hepatitis C we could not
detect HCV specific CD4+ T cells although this issue certainly
needs further study. Nor did we find any evidence for immune
escape at an individual level (patients AC1 and AC2) or at
a population level. Thus attractive hypotheses for the loss of viral
control in acute hepatitis C could either be exhaustion of HCV
specific T cells or a failure to establish stable memory CD4+ T
cells during the phase of viral control which would explain why
these cells do not expand when viremia returns and which is
supported by the observation that in all three cases with evolving
chronic hepatitis C CD4+ T cell function was lost before viral
recrudescence.
In conclusion, using a novel HLA-DR1 tetramer complexed
with an immunodominant CD4+ T cell epitope, we could show
that HCV specific CD4+ T cells are induced in each patient with
acute hepatitis C irrespective of outcome. Whereas spontaneous
viral clearance is associated with long term maintenance of
tetramer+ CD4+ T cells, early loss of function followed by
depletion of tetramer+ CD4+ T cells is observed in patients with
evolving chronic hepatitis C. The impact of such T cell loss may be
very significant, undermining both CD8+ T cell-mediated and B
cell mediated immune responses in the long term which can be
associated with accentuated escape from CD8+ T cells as has been
observed in model and natural infection [20,24]. The mechanism
behind this loss includes, as described above, excess stimulation by
antigen, but an additional mechanism must also be sought to
explain the differences from HIV. This may potentially be due to
the specific environment where priming occurs, some activity of an
HCV-derived protein such as core, defects in antigen-presenta-
tion, or a liver-specific ‘‘tolerance’’ effect. The new HLA class II
tetramer technology will allow the further dissection of the
mechanism behind this striking phenomenon which may hold
the key to understanding HCV persistence.
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